CO6160338A2 - Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico - Google Patents
Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermicoInfo
- Publication number
- CO6160338A2 CO6160338A2 CO09030399A CO09030399A CO6160338A2 CO 6160338 A2 CO6160338 A2 CO 6160338A2 CO 09030399 A CO09030399 A CO 09030399A CO 09030399 A CO09030399 A CO 09030399A CO 6160338 A2 CO6160338 A2 CO 6160338A2
- Authority
- CO
- Colombia
- Prior art keywords
- therapeutic composition
- egf receptor
- antibody against
- interferon
- therapy
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 10
- 230000001225 therapeutic effect Effects 0.000 title abstract 10
- 102000009024 Epidermal Growth Factor Human genes 0.000 title 1
- 101800003838 Epidermal growth factor Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 229940116977 epidermal growth factor Drugs 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 title 1
- 102000001301 EGF receptor Human genes 0.000 abstract 6
- 108060006698 EGF receptor Proteins 0.000 abstract 6
- 102000014150 Interferons Human genes 0.000 abstract 6
- 108010050904 Interferons Proteins 0.000 abstract 6
- 229940079322 interferon Drugs 0.000 abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940047124 interferons Drugs 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
1.- Una composición terapéutica útil en el tratamiento del cáncer caracterizada porque comprende la administración simultánea o secuencial de un anticuerpo contra el receptor del EGF y uno o más interferones del tipo 1.2.- La composición terapéutica de la reivindicación 1, caracterizada porque comprende un anticuerpo contra el receptor del EGF, interferón y un excipiente adecuado para su administración por vía intravenosa.3.- La composición terapéutica de las reivindicaciones 1 y 2, caracterizada porque el anticuerpo monoclonal contra el receptor del EGF es un anticuerpo quimérico. 4.- La composición terapéutica de la reivindicación 3 caracterizada porque el anticuerpo monoclonal contra el receptor del EGF es un anticuerpo humanizado.5.- La composición terapéutica de la reivindicación 4 caracterizada porque el anticuerpo monoclonal contra el receptor del EGF es el anticuerpo humanizado hR3 producido por la línea celular con numero de depósito 951110101.6.- La composición terapéutica de la reivindicación 1 y 2 caracterizada porque el interferón es de tipo 1.7.- La composición terapéutica de la reivindicación 6 caracterizada porque el interferón es INF-a humano.8.- La composición terapéutica de la reivindicación 7 caracterizada porque el interferón es INF- a humano recombinante. 9.- Una composición terapéutica caracterizada porque comprende el anticuerpo monoclonal HR3 contra el receptor de EGF producido por la línea celular con no. de Depósito 951110101 y el interferón INF-a humano recombinante.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20060190A CU23612A1 (es) | 2006-09-29 | 2006-09-29 | Combinaciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6160338A2 true CO6160338A2 (es) | 2010-05-20 |
Family
ID=40223744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09030399A CO6160338A2 (es) | 2006-09-29 | 2009-03-25 | Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20100047207A1 (es) |
| EP (1) | EP2070547B1 (es) |
| KR (1) | KR101482957B1 (es) |
| CN (2) | CN101678099A (es) |
| AR (1) | AR063011A1 (es) |
| AU (1) | AU2007302429B2 (es) |
| BR (1) | BRPI0717142A2 (es) |
| CA (1) | CA2664795C (es) |
| CL (1) | CL2007002797A1 (es) |
| CO (1) | CO6160338A2 (es) |
| CR (1) | CR10753A (es) |
| CU (1) | CU23612A1 (es) |
| MA (1) | MA30811B1 (es) |
| MX (1) | MX2009003159A (es) |
| PE (1) | PE20080674A1 (es) |
| TN (1) | TN2009000104A1 (es) |
| TR (1) | TR200902344T1 (es) |
| UY (1) | UY30616A1 (es) |
| WO (1) | WO2008037225A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0914209A2 (pt) * | 2008-06-20 | 2015-11-03 | Centro Inmunologia Molecular | inibidor do receptor do fator de crscimento epidérmico, linha celular, composição farmacêutica, usos do inibidor e de um anticorpo e método |
| CN103536917B (zh) * | 2013-10-30 | 2015-03-11 | 苏州丁孚靶点生物技术有限公司 | 干扰素在治疗肿瘤中的用途及相关的产品和方法 |
| BR112018001679A2 (en) * | 2015-07-27 | 2018-09-18 | Innocimab Pte Ltd | method of treating a patient population, composition, monoclonal antibody, method of predicting whether a patient suffering from pancreatic ductal adenocarcinoma will be unresponsive to treatment with an antibody, and method of treating a patient population |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| CA2129533A1 (en) * | 1992-02-10 | 1993-08-19 | Douglas Testa | Improved alpha interferon composition and method for its production from human peripheral blood leukocytes |
| US20040127470A1 (en) * | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
| US6949520B1 (en) * | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| SK14632003A3 (sk) * | 2001-05-08 | 2004-03-02 | Merck Patent Gmbh | Kombinovaná terapia pri použití anti-EGFR protilátok a antihormonálnych činidiel |
| US20060134064A1 (en) * | 2004-12-20 | 2006-06-22 | David Goldstein | Combined treatment with interferon-alpha and an epidermal growth factor receptor kinase inhibitor |
| US20110189178A1 (en) * | 2010-02-04 | 2011-08-04 | Xencor, Inc. | Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions |
-
2006
- 2006-09-29 CU CU20060190A patent/CU23612A1/es unknown
-
2007
- 2007-09-26 AR ARP070104260A patent/AR063011A1/es unknown
- 2007-09-27 PE PE2007001310A patent/PE20080674A1/es not_active Application Discontinuation
- 2007-09-27 MX MX2009003159A patent/MX2009003159A/es active IP Right Grant
- 2007-09-27 CN CN200780036290A patent/CN101678099A/zh active Pending
- 2007-09-27 CL CL200702797A patent/CL2007002797A1/es unknown
- 2007-09-27 KR KR1020097007699A patent/KR101482957B1/ko not_active Expired - Fee Related
- 2007-09-27 EP EP07817381.2A patent/EP2070547B1/en not_active Not-in-force
- 2007-09-27 CN CN2012104701143A patent/CN102940883A/zh active Pending
- 2007-09-27 AU AU2007302429A patent/AU2007302429B2/en not_active Ceased
- 2007-09-27 US US12/442,608 patent/US20100047207A1/en not_active Abandoned
- 2007-09-27 CA CA2664795A patent/CA2664795C/en not_active Expired - Fee Related
- 2007-09-27 WO PCT/CU2007/000017 patent/WO2008037225A1/es not_active Ceased
- 2007-09-27 TR TR2009/02344T patent/TR200902344T1/xx unknown
- 2007-09-27 BR BRPI0717142-0A patent/BRPI0717142A2/pt not_active IP Right Cessation
- 2007-09-28 UY UY30616A patent/UY30616A1/es not_active Application Discontinuation
-
2009
- 2009-03-25 CO CO09030399A patent/CO6160338A2/es unknown
- 2009-03-27 TN TN2009000104A patent/TN2009000104A1/fr unknown
- 2009-04-23 MA MA31815A patent/MA30811B1/fr unknown
- 2009-04-29 CR CR10753A patent/CR10753A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TN2009000104A1 (en) | 2010-08-19 |
| KR20090058566A (ko) | 2009-06-09 |
| MX2009003159A (es) | 2009-04-06 |
| CR10753A (es) | 2009-10-15 |
| AU2007302429B2 (en) | 2013-10-03 |
| CA2664795C (en) | 2014-06-17 |
| TR200902344T1 (tr) | 2009-08-21 |
| AU2007302429A1 (en) | 2008-04-03 |
| CA2664795A1 (en) | 2008-04-03 |
| MA30811B1 (fr) | 2009-10-01 |
| CN102940883A (zh) | 2013-02-27 |
| US20100047207A1 (en) | 2010-02-25 |
| PE20080674A1 (es) | 2008-07-23 |
| WO2008037225A1 (es) | 2008-04-03 |
| UY30616A1 (es) | 2008-05-02 |
| EP2070547A1 (en) | 2009-06-17 |
| BRPI0717142A2 (pt) | 2013-10-15 |
| KR101482957B1 (ko) | 2015-01-15 |
| CL2007002797A1 (es) | 2008-04-18 |
| CN101678099A (zh) | 2010-03-24 |
| EP2070547A4 (en) | 2011-11-02 |
| CU23612A1 (es) | 2010-12-08 |
| EP2070547B1 (en) | 2013-04-24 |
| AR063011A1 (es) | 2008-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY206158A (en) | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer | |
| AR115083A1 (es) | Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1 | |
| NZ599792A (en) | Immunomodulatory polypeptides derived from il- 2 and their use thereof in the therapeutic of cancer and chronic infections | |
| MY145042A (en) | Humanized monoclonal antibodies to hepatocyte growth factor | |
| WO2018157171A3 (en) | Compositions, articles of manufacture and methods related to dosing in cell therapy | |
| MX2020003888A (es) | Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos. | |
| RU2012137498A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| MX2020006715A (es) | Anticuerpos especificos del heterodimero de cd3-delta/epsilon. | |
| WO2020076969A3 (en) | Anti-lap antibody variants and uses thereof | |
| AU2015219495B2 (en) | Disease therapy by inducing immune response to Trop-2 expressing cells | |
| HRP20220748T1 (hr) | Anti-vista antitijela i fragmenti | |
| SG170730A1 (en) | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 | |
| WO2014186469A3 (en) | Human application of engineered chimeric antigen receptor (car) t-cells | |
| NZ602166A (en) | Antibodies to il-6 and use thereof | |
| MX2025001919A (es) | Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados | |
| ATE471946T1 (de) | Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2 | |
| UA94403C2 (ru) | Человеческое моноклональное антитело, которое нейтрализует gm-csf | |
| NZ593926A (en) | Methods and compositions based on shiga toxin type 2 protein | |
| PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
| WO2020232427A3 (en) | Therapeutic compositions and methods for treating cancer in combination with analogs of interleukin proteins | |
| WO2017096327A3 (en) | Compositions and methods for reducing immune responses against chimeric antigen receptors | |
| MX2019014375A (es) | Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo. | |
| HRP20250113T1 (hr) | Režim doziranja za gp100-specifični tcr - anti-cd3 scfv fuzijski protein | |
| CO6160338A2 (es) | Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico | |
| MX2023015471A (es) | Conjugados de anticuerpo-farmaco que comprenden anticuerpos humanizados que eligen como blanco la proteina asociada al receptor activador de plasminogeno tipo uroquinasa (uparap). |